Dalbavancin Injection, Powder, Lyophilized, For Solution
Product Images NDC 71839-144

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Dalbavancin (NDC 71839-144). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Be Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton (Carton)

This is a description for Dalbavancin for Injection, a medication packaged in a sterile single-dose vial with 500 mg per vial. It is intended for intravenous infusion only. The package contains dalbavancin HCl powder equivalent to 500 mg of dalbavancin, along with lactose monohydrate and mannitol as excipients. The reconstituted solution should be diluted with 5% Dextrose Injection to a final concentration of 1 to 5 mg/mL, and the total infusion time should not exceed 48 hours. It's important not to confuse this medication with others or electrolytes. The dosage and administration details are available in the full prescribing information.*

FDA Label Image

Figure1 (Dalbafigure1)

FDA Label Image

Logo (Dalbalogo)

FDA Label Image

Vial Label (Vial)

This text provides important information about Dalbavancin for injection including NDC code, storage instructions, reconstitution guidelines, infusion details, and cautions about co-infusion with other medications or electrolytes. It also states the dosage and administration information and lists the distributor as BE Pharmaceuticals Inc. It recommends consulting the full prescribing information before use.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.